(LUMO) – Press Releases
-
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
-
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
-
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
-
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
-
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
-
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
-
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
-
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
-
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
-
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
-
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
-
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
-
Lumos Pharma Announces Participation in Investor Conferences in September
-
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
-
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
-
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
-
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
-
Lumos Pharma Announces Departure of Chief Medical Officer
-
Lumos Pharma Announces Departure of Chief Medical Officer
-
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
-
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
-
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
-
Lumos Pharma to Participate in World Orphan Drug Congress USA
-
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
-
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
-
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
-
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
-
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
-
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
-
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
-
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
-
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
-
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
-
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
-
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
-
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
-
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
-
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
-
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
-
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
Back to LUMO Stock Lookup
